GH Research Surges 22% After FDA Lift, Analyst Buy Boosts 2026 Phase 3 Momentum
GH Research’s FDA lift of its GH001 IND clears a path to global Phase 3, sparking a 22% after‑hours rally and analyst “Buy” support, hinting at major upside.
3 minutes to read